Epstein Secrets

ing on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

PP and EIDL - Investigations, Oversight, and Regulations Subcommittee hybrid hearing on 'Preventing Fraud and Abuse of PPP and EIDL: An Update with the SBA Office of Inspector General and the Government Accountability Office', with testimony from Small Business Administration Inspector General Mike Ware; and GAO Director

ring on `unsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

P and EIDL' - Investigations, Oversight, and Regulations Subcommittee hybrid hearing on 'Preventing Fraud and Abuse of PPP and EIDL: An Update with the SBA Office of Inspector General and the Government Accountability Office', with testimony from Small Business Administration Inspector General Mike Ware; and GAO Director

ng on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

Investigations, Oversight, and Regulations Subcommittee hybrid hearing on EFTA01658535 'Preventing Fraud and Abuse of PPP and EIDL: An Update with the SBA Office of Inspector General and the Government Accountability Office', with testimony from Small Business Administration Inspector General Mike Ware; and GAO Director